Raymond James Financial
VERV

Raymond James Financial’s Verve Therapeutics VERV Stock Holding History

Raymond James Financial’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,288
Closed -$70.6K – 6716
2025
Q2 		$70.6K Sell
6,288
-5,000
-44% -$28.5K ﹤0.01% 5032
2025
Q1 		$51.6K Buy
+11,288
New +$75.6K ﹤0.01% 4638

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Raymond James Financial's VERV Position: Q3 2025 in Review

Raymond James Financial sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 6,288 shares — an estimated $70.6K sold.

Raymond James Financial first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $70.6K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Raymond James Financial reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 6,288 Verve Therapeutics shares in Q3 2025, an estimated $70.6K.
  • Raymond James Financial first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Raymond James Financial's Verve Therapeutics position peaked at $70.6K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.